STOCK TITAN

Bellerophon to Present at the H.C. Wainwright Global Life Sciences Conference

(Neutral)
(Neutral)
Tags
conferences

Rhea-AI Summary

Bellerophon Therapeutics (Nasdaq: BLPH) announced that CEO Fabian Tenenbaum will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand starting March 9, 2021, on the company’s website. Bellerophon focuses on developing innovative therapies for cardiopulmonary and infectious diseases, including its proprietary INOpulse® program, a pulsatile nitric oxide delivery system. For more information, visit bellerophon.com.

Loading...
Loading translation...

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

  • None.

Negative

  • None.

News Market Reaction – BLPH

+0.31%
+0.31% News Effect

On the day this news was published, BLPH gained 0.31%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

WARREN, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021.

The presentation will be available on-demand beginning on Tuesday, March 9, 2021, in the Investors section on the Company’s website at www.bellerophon.com.

About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.

Contacts

At W2O Group: At LifeSci Advisors:
Julie Normart Brian Ritchie
(559) 974-3245(212) 915-2578
jnormart@w2ogroup.combritchie@lifesciadvisors.com


FAQ

When is Bellerophon Therapeutics presenting at the H.C. Wainwright Global Life Sciences Conference?

Bellerophon Therapeutics will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

Where can I watch Bellerophon Therapeutics' presentation?

The presentation will be available on-demand on Bellerophon Therapeutics' website starting March 9, 2021.

What is the focus of Bellerophon Therapeutics?

Bellerophon Therapeutics focuses on developing treatments for cardiopulmonary and infectious diseases.

What is the INOpulse® program by Bellerophon?

The INOpulse® program is Bellerophon Therapeutics' proprietary pulsatile nitric oxide delivery system.